{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:08:04Z","timestamp":1793164084178,"version":"4.5.0"},"reference-count":233,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Inflammatory lung diseases represent a persistent burden for patients and the global healthcare system. The combination of high morbidity, (partially) high mortality and limited innovations in the last decades, have resulted in a great demand for new therapeutics. Are therapeutic IgA antibodies possibly a new hope in the treatment of inflammatory lung diseases? Current research increasingly unravels the elementary functions of IgA as protector against infections and as modulator of overwhelming inflammation. With a focus on IgA, this review describes the pathological alterations in mucosal immunity and how they contribute to chronic inflammation in the most common inflammatory lung diseases. The current knowledge of IgA functions in the circulation, and particularly in the respiratory mucosa, are summarized. The interplay between neutrophils and IgA seems to be key in control of inflammation. In addition, the hurdles and benefits of therapeutic IgA antibodies, as well as the currently known clinically used IgA preparations are described. The data highlighted here, together with upcoming research strategies aiming at circumventing the current pitfalls in IgA research may pave the way for this promising antibody class in the application of inflammatory lung diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1127339","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T01:57:36Z","timestamp":1679882256000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["A new hope? Possibilities of therapeutic IgA antibodies in the treatment of inflammatory lung diseases"],"prefix":"10.3389","volume":"14","author":[{"given":"Fabian","family":"Bohl\u00e4nder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1513\/pats.2306032","article-title":"Mucosal immunity in asthma and chronic obstructive pulmonary disease: A role for immunoglobulin a","volume":"1","author":"Pilette","year":"2004","journal-title":"Proc Am Thorac Soc"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.3390\/cells11081324","article-title":"Secretory immunoglobulin a immunity in chronic obstructive respiratory diseases","volume":"11","author":"de Fays","year":"2022","journal-title":"Cells."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.957107","article-title":"Mucosal immunity: The missing link in comprehending SARS-CoV-2 infection and transmission","volume":"13","author":"Russell","year":"2022","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/sci3040045","article-title":"Replacement strategies for animal studies in inhalation testing","volume":"3","author":"Fr\u00f6hlich","year":"2021","journal-title":"Sci."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30105-3","article-title":"Prevalence and attributable health burden of chronic respiratory diseases, 1990\u20132017: a systematic analysis for the global burden of disease study 2017","volume":"8","author":"Soriano","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/bjaed\/mkv052","article-title":"Severe community-acquired pneumonia","volume":"16","author":"Morgan","year":"2016","journal-title":"BJA Educ"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3390\/ani10081259","article-title":"Preclinical development of orally inhaled drugs (OIDs)\u2013are animal models predictive or shall we move towards In vitro non-animal models","volume":"10","author":"Movia","year":"2020","journal-title":"Animals"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1593538","article-title":"Nonantibiotic adjunctive therapies for community-acquired pneumonia (Corticosteroids and beyond): Where are we with them","volume":"37","author":"Sibila","year":"2016","journal-title":"Semin Respir Crit Care Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-022-08921-5","article-title":"Risk and protective factors for COVID-19 morbidity, severity, and mortality","volume":"64","author":"Zhang","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1023\/A:1009851919871","article-title":"IgA\/IgM and secretory immunity","volume":"3","author":"R\u00fcssmann","year":"1999","journal-title":"Sepsis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.09.046","article-title":"Structure and function of immunoglobulins","volume":"125","author":"Schroeder","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1023\/A:1009899803032","article-title":"Structure and function of immunoglobulins","volume":"3","author":"Sp\u00e4th","year":"1999","journal-title":"Sepsis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/antib8040057","article-title":"IgA: Structure, function, and developability","volume":"8","author":"de Sousa-Pereira","year":"2019","journal-title":"Antibodies."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.07.093","article-title":"Functional and structural characteristics of secretory IgA antibodies elicited by mucosal vaccines against influenza virus","volume":"35","author":"Suzuki","year":"2017","journal-title":"Vaccine."},{"key":"B15","doi-asserted-by":"publisher","first-page":"892","DOI":"10.7326\/0003-4819-106-6-892","article-title":"Intravascular and mucosal immunoglobulin a: Two separate but related systems of immune defense","volume":"106","author":"Conley","year":"1987","journal-title":"Ann Intern Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00185\/abstract","article-title":"Multi-faceted functions of secretory IgA at mucosal surfaces","volume":"4","author":"Corth\u00e9sy","year":"2013","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2384","article-title":"The role of secretory antibodies in infection immunity","volume":"8","author":"Strugnell","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41467-019-13992-8","article-title":"IgA subclasses have different effector functions associated with distinct glycosylation profiles","volume":"11","author":"Steffen","year":"2020","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.4.16092","article-title":"Immunoglobulin a: A next generation of therapeutic antibodies","volume":"3","author":"Bakema","year":"2011","journal-title":"mAbs"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2011.39","article-title":"Structure and function relationships in IgA","volume":"4","author":"Woof","year":"2011","journal-title":"Mucosal Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.410811","article-title":"Human plasma-derived polymeric IgA and IgM antibodies associate with secretory component to yield biologically active secretory-like antibodies","volume":"288","author":"Longet","year":"2013","journal-title":"J Biol Chem"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3083.2000.00790.x","article-title":"Role of J chain in secretory immunoglobulin formation","volume":"52","author":"Johansen","year":"2000","journal-title":"Scand J Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.3390\/cells10123603","article-title":"Immunoglobulin a mucosal immunity and altered respiratory epithelium in cystic fibrosis","volume":"10","author":"Gohy","year":"2021","journal-title":"Cells."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/sji.12499","article-title":"Selective IgA deficiency: Epidemiology, pathogenesis, clinical phenotype, diagnosis, prognosis and management","volume":"85","author":"Yazdani","year":"2017","journal-title":"Scand J Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.649112\/full","article-title":"Innate mechanisms in selective IgA deficiency","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2022.852546","article-title":"The role of IgA in chronic upper airway disease: Friend or foe","volume":"3","author":"S\u00e1nchez Montalvo","year":"2022","journal-title":"Front Allergy"},{"key":"B27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000510251","article-title":"When therapeutic IgA antibodies might come of age","volume":"106","author":"Sterlin","year":"2021","journal-title":"Pharmacology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.10.005","article-title":"IgA deficiency and autoimmunity","volume":"13","author":"Singh","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3390\/medicina58010129","article-title":"Selective IgA deficiency and allergy: A fresh look to an old story","volume":"58","author":"Cinicola","year":"2022","journal-title":"Medicina (Mex)."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2217\/imt.14.67","article-title":"An update on the use of immunoglobulin for the treatment of immunodeficiency disorders","volume":"6","author":"Albin","year":"2014","journal-title":"Immunotherapy."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194924","article-title":"Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS","volume":"13","author":"Putcha","year":"2018","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201604-0759OC","article-title":"Secretory IgA deficiency in individual small airways is associated with persistent inflammation and remodeling","volume":"195","author":"Polosukhin","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201703-0561OC","article-title":"Bronchial epithelial IgA secretion is impaired in asthma","volume":"197","author":"Ladjemi","year":"2018","journal-title":"Role IL-4\/IL-13. Am J Respir Crit Care Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300864","article-title":"Secretory IgA induces tolerogenic dendritic cells through SIGNR1 dampening autoimmunity in mice","volume":"191","author":"Diana","year":"2013","journal-title":"J Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S329531","article-title":"Selective IgA deficiency a probable risk of recurrent chest infections in asthmatics","volume":"14","author":"Abo Ali","year":"2021","journal-title":"J Asthma Allergy"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2014.160","article-title":"Relationship between serum IgA level and allergy\/asthma","volume":"32","author":"Kim","year":"2017","journal-title":"Korean J Intern Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"102974","DOI":"10.1016\/j.ebiom.2020.102974","article-title":"Lung immunoglobulin a immunity dysregulation in cystic fibrosis","volume":"60","author":"Collin","year":"2020","journal-title":"EBioMedicine."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2016-000152","article-title":"Serum levels of immunoglobulins and severity of community-acquired pneumonia","volume":"3","author":"de la Torre","year":"2016","journal-title":"BMJ Open Respir Res"},{"key":"B39","first-page":"818","article-title":"Intravenous immunoglobulin in community acquired pneumonia","volume":"38","author":"Farkhutdinov","year":"2011","journal-title":"Eur Respir J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.11.4.665-668.2004","article-title":"Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus","volume":"11","author":"Woo","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e22390","DOI":"10.1097\/MD.0000000000022390","article-title":"Immunoglobulins concentration and b cell counts as severity markers in adult community-acquired pneumonia: Cross sectional study","volume":"99","author":"Luchsinger","year":"2020","journal-title":"Med (Baltimore)."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.868973","article-title":"Serum immunoglobulins, pneumonia risk, and lung function in middle-aged and older individuals: A population-based cohort study","volume":"13","author":"Khan","year":"2022","journal-title":"Front Immunol"},{"key":"B43","article-title":"The role of Neutrophils and pathogens in the early onset-ventilator acquired pneumonia, based on analysis of bronchoalveolar lavage specimen","volume":"8","author":"Syarani","year":"2015","journal-title":"Int J PharmTech Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13500","article-title":"Characteristics and roles of severe acute respiratory syndrome coronavirus 2-specific antibodies in patients with different severities of coronavirus 19","volume":"202","author":"Huang","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26422","article-title":"Closing the serological gap in the diagnostic testing for COVID-19: The value of anti-SARS-CoV-2 IgA antibodies","volume":"93","author":"Infantino","year":"2021","journal-title":"J Med Virol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2020.04.026","article-title":"IgA-ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study","volume":"507","author":"Padoan","year":"2020","journal-title":"Clin Chim Acta"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd2223","article-title":"IgA dominates the early neutralizing antibody response to SARS-CoV-2","volume":"13","author":"Sterlin","year":"2021","journal-title":"Sci Transl Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3390\/pathogens11040397","article-title":"Mucosal antibody response to SARS-CoV-2 in paediatric and adult patients: A longitudinal study","volume":"11","author":"Chan","year":"2022","journal-title":"Pathogens."},{"key":"B49","doi-asserted-by":"publisher","first-page":"100779","DOI":"10.1016\/j.xcrm.2022.100779","article-title":"Longitudinal characterization of circulating neutrophils uncovers phenotypes associated with severity in hospitalized COVID-19 patients","volume":"3","author":"LaSalle","year":"2022","journal-title":"Cell Rep Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3201\/eid2607.200841","article-title":"Severe acute respiratory syndrome Coronavirus 2\u2212specific atibody responses in coronavirus disease patients","volume":"26","author":"Okba","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.12306","article-title":"Serum IgA fc effector functions in infectious disease and cancer","volume":"98","author":"Davis","year":"2020","journal-title":"Immunol Cell Biol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61382-8","article-title":"COPD exacerbations: defining their cause and prevention","volume":"370","author":"Wedzicha","year":"2007","journal-title":"Lancet"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00595","article-title":"Progress in model systems of cystic fibrosis mucosal inflammation to understand aberrant neutrophil activity","volume":"11","author":"Laucirica","year":"2020","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.4913","article-title":"Secretory component is cleaved by neutrophil serine proteinases but its epithelial production is increased by neutrophils through NF-\u03baB\u2013 and p38 mitogen-activated protein kinase\u2013dependent mechanisms","volume":"28","author":"Pilette","year":"2003","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.21037\/jeccm.2018.11.06","article-title":"Management of pneumonia in intensive care","volume":"2","author":"Morris","year":"2018","journal-title":"J Emerg Crit Care Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1186\/s13054-018-2290-8","article-title":"Neutrophil extracellular traps (NETs) are increased in the alveolar spaces of patients with ventilator-associated pneumonia","volume":"22","author":"Mikacenic","year":"2018","journal-title":"Crit Care"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/arh.2017.08.01","article-title":"Current and emerging evidence for immunomodulatory therapy in community-acquired pneumonia","volume":"1","author":"Woods","year":"2017","journal-title":"Ann Res Hosp."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97065","article-title":"Antibiotic treatment\u2013induced secondary IgA deficiency enhances susceptibility to pseudomonas aeruginosa pneumonia","volume":"128","author":"Robak","year":"2018","journal-title":"J Clin Invest."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2009.040","article-title":"Sequence of immunoglobulin isotype exposure modulates inflammatory response to bacteria and lipopolysaccharide in vitro","volume":"11","author":"Diebel","year":"2010","journal-title":"Surg Infect"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1097\/01.ta.0000187797.38327.78","article-title":"Immunoglobulin a modulates inflammatory responses in an in vitro model of pneumonia","volume":"59","author":"Diebel","year":"2005","journal-title":"J Trauma."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.577442\/full","article-title":"Immunomodulation for severe COVID-19 pneumonia: The state of the art","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7137a4","article-title":"Mortality risk among patients hospitalized primarily for COVID-19 during the omicron and delta variant pandemic periods \u2014 united states, April 2020\u2013June 2022","volume":"71","author":"Adjei","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/jamainternmed.2022.3351","article-title":"COVID-19 disease severity in persons infected with omicron BA.1 and BA.2 sublineages and association with vaccination status","volume":"182","author":"Butt","year":"2022","journal-title":"JAMA Intern Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00367-20","article-title":"COVID-19 hyperinflammation: What about neutrophils","volume":"5","author":"Didangelos","year":"2020","journal-title":"mSphere."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.680134\/full","article-title":"Neutrophils and COVID-19: Active participants and rational therapeutic targets","volume":"12","author":"Hazeldine","year":"2021","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-020-0530-3","article-title":"COVID-19 infection: the perspectives on immune responses","volume":"27","author":"Shi","year":"2020","journal-title":"Cell Death Differ"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24907","article-title":"Immune-related factors associated with pneumonia in 127 children with coronavirus disease 2019 in wuhan","volume":"55","author":"Li","year":"2020","journal-title":"Pediatr Pulmonol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1128\/mBio.00281-21","article-title":"COVID-19 severity is associated with differential antibody fc-mediated innate immune functions","volume":"12","author":"Adeniji","year":"2021","journal-title":"mBio."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.618685","article-title":"Distinct features and functions of systemic and mucosal humoral immunity among SARS-CoV-2 convalescent individuals","volume":"11","author":"Butler","year":"2021","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.611337","article-title":"Mucosal immunity in COVID-19: A neglected but critical aspect of SARS-CoV-2 infection","volume":"11","author":"Russell","year":"2020","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2001526","DOI":"10.1183\/13993003.01526-2020","article-title":"Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients","volume":"56","author":"Yu","year":"2020","journal-title":"Eur Respir J"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.595343","article-title":"In nasal mucosal secretions, distinct IFN and IgA responses are found in severe and mild SARS-CoV-2 infection","volume":"12","author":"dos Santos J de","year":"2021","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2020.08.07.20170258","DOI":"10.1101\/2020.08.07.20170258","article-title":"Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19","volume":"26","author":"Varadhachary","year":"2020","journal-title":"medRxiv"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.842468","article-title":"Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1\u03b2 associate with COVID-19 fatal outcome: A cross-sectional analysis","volume":"13","author":"Ruiz","year":"2022","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.1038\/s41467-021-27063-4","article-title":"Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization","volume":"12","author":"Lapuente","year":"2021","journal-title":"Nat Commun"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add4853","article-title":"Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination","volume":"7","author":"Tang","year":"2022","journal-title":"Sci Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.3390\/cells9122676","article-title":"IgA2 antibodies against SARS-CoV-2 correlate with NET formation and fatal outcome in severely diseased COVID-19 patients","volume":"9","author":"Staats","year":"2020","journal-title":"Cells."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1502353","article-title":"IgA complexes in plasma and synovial fluid of patients with rheumatoid arthritis induce neutrophil extracellular traps via Fc\u03b1RI","volume":"197","author":"Aleyd","year":"2016","journal-title":"J Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300261","article-title":"IgA enhances NETosis and release of neutrophil extracellular traps by polymorphonuclear cells via fc\u03b1 receptor I","volume":"192","author":"Aleyd","year":"2014","journal-title":"J Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"e2101497118","DOI":"10.1073\/pnas.2101497118","article-title":"IgA potentiates NETosis in response to viral infection","volume":"118","author":"Stacey","year":"2021","journal-title":"Proc Natl Acad Sci"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007008","article-title":"Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome","volume":"136","author":"Middleton","year":"2020","journal-title":"Blood."},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.06.007","article-title":"Neutrophil extracellular traps, local IL-8 expression, and cytotoxic T-lymphocyte response in the lungs of patients with fatal COVID-19","volume":"162","author":"Melero","year":"2022","journal-title":"Chest Infections"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab437","article-title":"Increased peripheral blood neutrophil activation phenotypes and neutrophil extracellular trap formation in critically ill coronavirus disease 2019 (COVID-19) patients: A case series and review of the literature","volume":"74","author":"Masso-Silva","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/5566826","article-title":"Neutrophil extracellular traps in fatal COVID-19-Associated lung injury","volume":"2021","author":"Obermayer","year":"2021","journal-title":"Dis Markers."},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12716","article-title":"Immunoglobulin a: magic bullet or Trojan horse","volume":"47","author":"Heineke","year":"2017","journal-title":"Eur J Clin Invest"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S266242","article-title":"IgA and Fc\u03b1RI: Versatile players in homeostasis, infection, and autoimmunity","volume":"9","author":"van Gool","year":"2021","journal-title":"ImmunoTargets Ther"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-022-01627-6","article-title":"Neutrophils as emerging protagonists and targets in chronic inflammatory diseases","volume":"71","author":"Rawat","year":"2022","journal-title":"Inflamm Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2011.36","article-title":"The human immunoglobulin a fc receptor Fc\u03b1RI: a multifaceted regulator of mucosal immunity","volume":"4","author":"Bakema","year":"2011","journal-title":"Mucosal Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00811","article-title":"Understanding fc receptor involvement in inflammatory diseases: From mechanisms to new therapeutic tools","volume":"10","author":"Ben Mkaddem","year":"2019","journal-title":"Front Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-07911-0_10","article-title":"IgA, IgA receptors, and their anti-inflammatory properties","volume":"382","author":"Mkaddem","year":"2014","journal-title":"Curr Topics Microbiol Immunol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1600-065X.2009.00832.x","article-title":"Inhibitory ITAMs as novel regulators of immunity","volume":"232","author":"Blank","year":"2009","journal-title":"Immunol Rev"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2001309","article-title":"Inhibitory ITAM signaling traps activating receptors with the phosphatase SHP-1 to form polarized \u201cInhibisome\u201d clusters","volume":"4","author":"Pfirsch-Maisonnas","year":"2011","journal-title":"Sci Signal"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.5.2861","article-title":"Human IgA activates the complement system Via the mannan-binding lectin pathway","volume":"167","author":"Roos","year":"2001","journal-title":"J Immunol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10875-009-9338-0","article-title":"Role of IgA and IgA fc receptors in inflammation","volume":"30","author":"Monteiro","year":"2010","journal-title":"J Clin Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830191210","article-title":"Anti-inflammatory activity of human IgA antibodies and their fab\u03b1 fragments: inhibition of IgG-mediated complement activation","volume":"19","author":"Russell","year":"1989","journal-title":"Eur J Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2011.41","article-title":"Secretory IgA\u2019s complex roles in immunity and mucosal homeostasis in the gut","volume":"4","author":"Mantis","year":"2011","journal-title":"Mucosal Immunol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.immuni.2004.11.017","article-title":"Identification of Fc\u03b1RI as an inhibitory receptor that controls inflammation","volume":"22","author":"Pasquier","year":"2005","journal-title":"Immunity."},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00275\/full","article-title":"Monomeric immunoglobulin a from plasma inhibits human Th17 responses In vitro independent of Fc\u03b1RI and DC-SIGN","volume":"8","author":"Saha","year":"2017","journal-title":"Front Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01925\/full","article-title":"Limited innovations after more than 65 years of immunoglobulin replacement therapy: Potential of IgA- and IgM-enriched formulations to prevent bacterial respiratory tract infections","volume":"9","author":"Langereis","year":"2018","journal-title":"Front Immunol [Internet]"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1622940","article-title":"Production, characterization, and in vivo half-life extension of polymeric IgA molecules in mice","volume":"11","author":"Lombana","year":"2019","journal-title":"mAbs."},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007427","article-title":"IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody","volume":"15","author":"Saito","year":"2019","journal-title":"PloS Pathog"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1503885112","article-title":"Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus","volume":"112","author":"Suzuki","year":"2015","journal-title":"Proc Natl Acad Sci"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1101\/2020.09.09.288555","article-title":"Enhanced SARS-CoV-2 neutralization by secretory IgA in vitro [Internet]","author":"Wang","year":"2020","journal-title":"bioRxiv"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00553","article-title":"IgA and Fc\u03b1RI: Pathological roles and therapeutic opportunities","volume":"10","author":"Breedveld","year":"2019","journal-title":"Front Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.549139","article-title":"Reconstituted human polyclonal plasma-derived secretory-like IgM and IgA maintain the barrier function of epithelial cells infected with an enteropathogen","volume":"289","author":"Longet","year":"2014","journal-title":"J Biol Chem"},{"key":"B107","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1651-2227.1994.tb13240.x","article-title":"The anti-inflammatory effect of an oral immunoglobulin (IgA-IgG) preparation and its possible relevance for the prevention of necrotizing enterocolitis","volume":"83","author":"Wolf","year":"1994","journal-title":"Acta Paediatr"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.5.2816","article-title":"IL-8 released constitutively by primary bronchial epithelial cells in culture forms an inactive complex with secretory component","volume":"167","author":"Marshall","year":"2001","journal-title":"J Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-011-9511-0","article-title":"Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: Results from a multicenter prospective cohort study","volume":"31","author":"Quinti","year":"2011","journal-title":"J Clin Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377945","article-title":"Morbidity and mortality in common variable immune deficiency over 4 decades","volume":"119","author":"Resnick","year":"2012","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S283832","article-title":"Polyvalent immunoglobulin as a potential treatment option for patients with recurrent COPD exacerbations","volume":"16","author":"Unninayar","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B112","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3390\/antib9040070","article-title":"Fc engineering strategies to advance IgA antibodies as therapeutic agents","volume":"9","author":"van Tetering","year":"2020","journal-title":"Antibodies."},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00704","article-title":"Potent fc receptor signaling by IgA leads to superior killing of cancer cells by neutrophils compared to IgG","volume":"10","author":"Brandsma","year":"2019","journal-title":"Front Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2004.01958.x","article-title":"IgA function - variations on a theme","volume":"113","author":"Woof","year":"2004","journal-title":"Immunology."},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.molbev.a040687","article-title":"Evolutionary rate of immunoglobulin alpha noncoding region is greater in hominoids than in old world monkeys","volume":"8","author":"Kawamura","year":"1991","journal-title":"Mol Biol Evol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)42525-2","article-title":"Concerted evolution of the primate immunoglobulin alpha-gene through gene conversion","volume":"267","author":"Kawamura","year":"1992","journal-title":"J Biol Chem"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2010.85","article-title":"Mouse and human intestinal immunity: same ballpark, different players; different rules, same score","volume":"4","author":"Gibbons","year":"2011","journal-title":"Mucosal Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.5.2731","article-title":"Of mice and not men: Differences between mouse and human immunology","volume":"172","author":"Mestas","year":"2004","journal-title":"J Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12962","article-title":"Monoclonal antibody-mediated killing of tumour cells by neutrophils","volume":"48","author":"Heemskerk","year":"2018","journal-title":"Eur J Clin Invest."},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2014.10.017","article-title":"IgGA: A \u201cCross-isotype\u201d engineered human fc antibody domain that displays both IgG-like and IgA-like effector functions","volume":"21","author":"Kelton","year":"2014","journal-title":"Chem Biol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.761816\/full","article-title":"IgA complexes induce neutrophil extracellular trap formation more potently than IgG complexes","volume":"12","author":"Gimpel","year":"2022","journal-title":"Front Immunol [Internet]"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2836(03)00149-9","article-title":"Bivalent binding of IgA1 to Fc\u03b1RI suggests a mechanism for cytokine activation of IgA phagocytosis","volume":"327","author":"Herr","year":"2003","journal-title":"J Mol Biol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.3390\/biomedicines9121828","article-title":"The functional role of IgA in the IgM\/IgA-enriched immunoglobulin preparation trimodulin","volume":"9","author":"Bohl\u00e4nder","year":"2021","journal-title":"Biomedicines."},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.700429","article-title":"Immunomodulation: Immunoglobulin preparations suppress hyperinflammation in a COVID-19 model via Fc\u03b3RIIA and Fc\u03b1RI","volume":"12","author":"Bohl\u00e4nder","year":"2021","journal-title":"Front Immunol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"102554","DOI":"10.1016\/j.autrev.2020.102554","article-title":"Convalescent plasma in covid-19: Possible mechanisms of action","volume":"19","author":"Rojas","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1007\/s00005-016-0422-x","article-title":"Clinical use and therapeutic potential of IVIG\/SCIG, plasma-derived IgA or IgM, and other alternative immunoglobulin preparations","volume":"65","author":"Sp\u00e4th","year":"2017","journal-title":"Arch Immunol Ther Exp (Warsz)."},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","author":"Gelfand","year":"2012","journal-title":"N Engl J Med"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology\u2013mode of action and clinical efficacy","volume":"11","author":"L\u00fcnemann","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxx039","article-title":"IVIG-mediated effector functions in autoimmune and inflammatory diseases","volume":"29","author":"Galeotti","year":"2017","journal-title":"Int Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1996.tb14231.x","article-title":"Oral IgA-IgG treatment of chronic non-specific diarrhoea in infants and children","volume":"85","author":"Casswall","year":"1996","journal-title":"Acta Paediatr"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM198807073190101","article-title":"Prevention of necrotizing enterocolitis in low-birth-weight infants by IgA-IgG feeding","volume":"319","author":"Eibl","year":"1988","journal-title":"N Engl J Med"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199805000-00004","article-title":"Intranasally administered immunoglobulin for the prevention of rhinitis in children","volume":"17","author":"Heikkinen","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5876(96)01472-3","article-title":"Upper respiratory infections in children: response to endonasal administration of IGA","volume":"39","author":"Giraudi","year":"1997","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3109\/00365549309008580","article-title":"Nasal administration of immunoglobulin as effective prophylaxis against infections in elite cross-country skiers","volume":"25","author":"Hemmingsson","year":"1993","journal-title":"Scand J Infect Dis"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-972838","article-title":"Effect of treatment with nasal lgA on the incidence of infectious disease in world-class canoeists","volume":"17","author":"Lindberg","year":"1996","journal-title":"Int J Sports Med"},{"key":"B137","doi-asserted-by":"publisher","first-page":"CD001816","DOI":"10.1002\/14651858.CD001816.pub3","article-title":"Oral immunoglobulin for preventing necrotizing enterocolitis in preterm and low birth weight neonates","volume":"2016","author":"Foster","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B138","article-title":"[Passive immunotherapy in risk of habitual abortion\u2013the course of maternal serum immunoglobulins]","volume":"118","author":"Kr\u00fcmmer","year":"1996","journal-title":"Zentralbl Gynakol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-963098","article-title":"Experimental study on the use of intravenous immunoglobulin (IVIg) in patients with steroid-resistant crohn\u2019s disease","volume":"45","author":"Chrissafidou","year":"2007","journal-title":"Z F\u00fcr Gastroenterol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1007\/BF01745575","article-title":"Dose-response relationship in the treatment of idiopathic thrombocytopenic purpura with intravenous immunoglobulin","volume":"65","author":"Emmerich","year":"1987","journal-title":"Klin Wochenschr"},{"key":"B141","doi-asserted-by":"publisher","first-page":"CD001090","DOI":"10.1002\/14651858.CD001090.pub2","article-title":"Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock","author":"Alejandria","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"B142","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13613-019-0501-3","article-title":"The clinical efficacy of intravenous IgM-enriched immunoglobulin (pentaglobin) in sepsis or septic shock: a meta-analysis with trial sequential analysis","volume":"9","author":"Cui","year":"2019","journal-title":"Ann Intensive Care"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000295263.12774.97","article-title":"Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock*","volume":"35","author":"Kreymann","year":"2007","journal-title":"Crit Care Med"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-018-5143-7","article-title":"Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study)","volume":"44","author":"Welte","year":"2018","journal-title":"Intensive Care Med"},{"key":"B145","article-title":"Efficacy and safety of trimodulin in subjects with severe COVID-19 (ESsCOVID) identifier: NCT04576728","volume-title":"ClinicalTrials.gov","year":"2020"},{"key":"B146","article-title":"Efficacy and safety of trimodulin (BT588) in subjects with moderate or severe COVID-19 (TRICOVID) identifier: NCT05531149","volume-title":"ClinicalTrials.gov","year":"2022"},{"key":"B147","first-page":"1","article-title":"Evaluation of pharmacokinetics and safety of the IgM enriched immunoglobulin concentrate BT086 in healthy volunteers-results of a multiple dose phase I study","volume":"72","author":"Schmiedl","year":"2011","journal-title":"Br J Pharmacol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1996.d01-793.x","article-title":"Anti-inflammatory properties of human serum IgA: induction of IL-1 receptor antagonist and fc alpha r (CD89)-mediated down-regulation of tumour necrosis factor-alpha (TNF-alpha) and IL-6 in human monocytes","volume":"105","author":"Wolf","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-199408000-00016","article-title":"Inhibition of receptor-dependent and receptor-independent generation of the respiratory burst in human neutrophils and monocytes by human serum IgA","volume":"36","author":"Wolf","year":"1994","journal-title":"Pediatr Res"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1086\/317423","article-title":"Relative neutralizing activity in polyspecific IgM, IgA, and IgG preparations against group a streptococcal superantigens","volume":"31","author":"Norrby-Teglund","year":"2000","journal-title":"Clin Infect Dis"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2018.06.005","article-title":"The use of IgM-enriched immunoglobulin in adult patients with sepsis","volume":"47","author":"Kakoullis","year":"2018","journal-title":"J Crit Care"},{"key":"B152","article-title":"[Level of immunoglobulins a, G and m in the postoperative period]","volume":"20","author":"Dressler","year":"1995","journal-title":"Anaesthesiol Reanim."},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1023255","article-title":"Das prim\u00e4re antiphospholipid-Antik\u00f6rper-Syndrom (APAK) in der schwangerschaft - erfolgreicher schwangerschaftsverlauf nach intraven\u00f6ser immunglobulingabe (IVIG)","volume":"56","author":"Rosen","year":"1996","journal-title":"Geburtshilfe Frauenheilkd."},{"key":"B154","article-title":"Therapy of crohn disease by immunomodulation with 7S immunoglobulins","author":"Schmidt","year":"1993","journal-title":"Immun Infekt."},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200209000-00005","article-title":"Comparison of intravenous immunoglobulin preparations on microglial function In vitro: More potent immunomodulatory capacity of an IgM\/IgA-enriched preparation","volume":"25","author":"Pul","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"B156","doi-asserted-by":"publisher","first-page":"P197","DOI":"10.1186\/s13054-022-03927-z","article-title":"IgM\/IgA-enriched immunoglobulins: more than an IVIg: about multimeric IgA, IgM & J-chain","volume":"26","author":"Bohl\u00e4nder","year":"2022","journal-title":"Crit Care"},{"key":"B157","first-page":"35","article-title":"Active transfer of polymeric immunoglobulins into the CVID lung following intravenous infusion of an IgA and IgM enriched IVIg","volume":"174","author":"Kiani-Alikhan","year":"2013","journal-title":"In Clin Exp Immunology;"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.04.032","article-title":"Immunoglobulin replacement therapy: Is there a role for IgA and IgM","volume":"130","author":"Kiani-Alikhan","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(83)90366-9","article-title":"Primary cultures of rat hepatocytes as a model system of canalicular development, bilary secretion, and intrahepatic cholestasis","volume":"84","author":"Gebhardt","year":"1983","journal-title":"Gastroenterology."},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13553","article-title":"Treatment with IgM-enriched intravenous immunoglobulins enhances clearance of stroke-associated bacterial lung infection","volume":"167","author":"McCulloch","year":"2022","journal-title":"Immunology"},{"key":"B161","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13613-020-00740-1","article-title":"Best-practice IgM- and IgA-enriched immunoglobulin use in patients with sepsis","volume":"10","author":"Nierhaus","year":"2020","journal-title":"Ann Intensive Care"},{"key":"B162","article-title":"Opsonic activity of a new intravenous immunoglobulin preparation: Pentaglobin compared with sandoglobulin","volume":"76","author":"Garbett","year":"1989","journal-title":"Clin Exp Immunol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1097\/shk.0b013e318067df15","article-title":"Effects of IgM-enriched solution on polymorphonuclear neutrophil function, bacterial clearance, and lung histology in endotoxemia","volume":"29","author":"Stehr","year":"2008","journal-title":"Shock."},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-73468-7_62","article-title":"Antibacterial and antitoxic efficancy of an IgM-enriched intravenous immunoglobulin preparation","author":"Stephan","year":"1989","journal-title":"Immune Consequences Trauma Shock Sepsis"},{"key":"B165","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-77405-8_151","article-title":"Antiendotoxic therapy with polyclonal and polyvalent immunoglobulins: In vitro and in vivo studies","volume-title":"Host defense dysfunction in trauma, shock and sepsis","author":"Berger","year":"1993"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160907","article-title":"IgM-enriched immunoglobulin attenuates systemic endotoxin activity in early severe sepsis: A before-after cohort study","volume":"11","author":"Wand","year":"2016","journal-title":"PloS One"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2012.08.268","article-title":"Polyvalent immunoglobulin significantly attenuated the formation of IL-1\u03b2 in escherichia coli-induced sepsis in pigs","volume":"218","author":"Barratt-Due","year":"2013","journal-title":"Immunobiology."},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.1998.00495.x","article-title":"Modulation of alloimmune response in vitro by an IgM-enriched immunoglobulin preparation (Pentaglobin)","volume":"94","author":"Nachbaur","year":"1998","journal-title":"Immunology."},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1007\/s004330050115","article-title":"Protective capacity of a IgM\/IgA-enriched polyclonal immunoglobulin-G preparation in endotoxemia","volume":"198","author":"Oesser","year":"1998","journal-title":"Res Exp Med (Berl)."},{"key":"B170","doi-asserted-by":"publisher","first-page":"151897","DOI":"10.1016\/j.imbio.2019.12.006","article-title":"Titration of igs contained in an intravenous IgM-enriched preparation against selected pathogens involved in sepsis","volume":"225","author":"Stracquadanio","year":"2020","journal-title":"Immunobiology."},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.3.942","article-title":"Immunoglobulin m\u2013enriched human intravenous immunoglobulin prevents complement activation In vitro and In vivo in a rat model of acute inflammation","volume":"93","author":"Rieben","year":"1999","journal-title":"Blood."},{"key":"B172","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1034\/j.1399-3089.2003.00063.x","article-title":"IgM-enriched human intravenous immunoglobulin strongly inhibits complement-dependent porcine cell cytotoxicity mediated by human xenoreactive antibodies: IVIgM inhibits cytotoxicity of human serum to pig cells","volume":"10","author":"Roos","year":"2003","journal-title":"Xenotransplantation."},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1046\/j.1399-3089.2003.00098.x","article-title":"Immunoglobulin m-enriched intravenous immunoglobulin inhibits classical pathway complement activation, but not bactericidal activity of human serum","volume":"11","author":"Walpen","year":"2004","journal-title":"Xenotransplantation."},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2017.09.002","article-title":"A double blind randomized experimental study on the use of IgM-enriched polyclonal immunoglobulins in an animal model of pneumonia developing shock","volume":"222","author":"Vaschetto","year":"2017","journal-title":"Immunobiology."},{"key":"B175","doi-asserted-by":"publisher","first-page":"12926","DOI":"10.1038\/s41598-021-92412-8","article-title":"Immunomodulatory effects of different intravenous immunoglobulin preparations in chronic lymphocytic leukemia","volume":"11","author":"Colado","year":"2021","journal-title":"Sci Rep"},{"key":"B176","doi-asserted-by":"publisher","first-page":"11731","DOI":"10.1038\/s41598-022-15676-8","article-title":"A human IgM enriched immunoglobulin preparation, pentaglobin, reverses autoimmune diabetes without immune suppression in NOD mice","volume":"12","author":"Wilson","year":"2022","journal-title":"Sci Rep"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-92278-2_10","article-title":"IgM-enriched immunoglobulins in sepsis","author":"Esen","year":"2009","journal-title":"Intensive Care Med"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.10.013","article-title":"Endogenous immunoglobulins and sepsis: New perspectives for guiding replacement therapies","volume":"46","author":"Bermejo-Martin","year":"2015","journal-title":"Int J Antimicrob Agents."},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12265","article-title":"Immunoglobulins IgG1, IgM and IgA: a synergistic team influencing survival in sepsis","volume":"276","author":"Bermejo-Mart\u00edn","year":"2014","journal-title":"J Intern Med"},{"key":"B180","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1080\/21645515.2019.1711298","article-title":"Clinical, laboratory features and prognosis of children receiving IgM-enriched immunoglobulin (3 days vs. 5 days) as adjuvant treatment for serious infectious disease in pediatric intensive care unit: a retrospective single-center experience (PIGMENT study)","volume":"16","author":"Abdullayev","year":"2020","journal-title":"Hum Vaccines Immunother."},{"key":"B181","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1824-7288-39-63","article-title":"Are IgM-enriched immunoglobulins an effective adjuvant in septic VLBW infants","volume":"39","author":"Capasso","year":"2013","journal-title":"Ital J Pediatr"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1093\/tropej\/fmi011","article-title":"Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: A prospective study in a pediatric intensive care unit","volume":"51","author":"El-Nawawy","year":"2005","journal-title":"J Trop Pediatr"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.21276\/sb.2019.5.7.9","article-title":"A study to see the efficacy of IGM enriched IVIG in reducing mortality in neonatal sepsis","volume":"5","author":"Pal","year":"2019","journal-title":"Sch Bull"},{"key":"B184","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13613-018-0466-7","article-title":"Effects of the timing of administration of IgM- and IgA-enriched intravenous polyclonal immunoglobulins on the outcome of septic shock patients","volume":"8","author":"Berlot","year":"2018","journal-title":"Ann Intensive Care"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00388","article-title":"Administration of immunoglobulins in SARS-CoV-2-Positive patient is associated with fast clinical and radiological healing: Case report","volume":"7","author":"Carannante","year":"2020","journal-title":"Front Med"},{"key":"B186","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3390\/antibiotics10080930","article-title":"Treating critically ill patients experiencing SARS-CoV-2 severe infection with ig-m and ig-a enriched ig-G infusion","volume":"10","author":"Corona","year":"2021","journal-title":"Antibiotics."},{"key":"B187","doi-asserted-by":"publisher","first-page":"107968","DOI":"10.1016\/j.intimp.2021.107968","article-title":"Impact of pentaglobin in severe COVID 19 pneumonia- a prospective study","volume":"99","author":"Joshi","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B188","doi-asserted-by":"publisher","first-page":"107998","DOI":"10.1016\/j.intimp.2021.107998","article-title":"IgM-enriched immunoglobulin in COVID-19: Case series of 15 severely ill SARS-CoV-2-infected patients","volume":"99","author":"Tabarsi","year":"2021","journal-title":"Int Immunopharmacol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s13054-022-04059-0","article-title":"Intravenous IgM-enriched immunoglobulins in critical COVID-19: a multicentre propensity-weighted cohort study","volume":"26","author":"Rahmel","year":"2022","journal-title":"Crit Care"},{"key":"B190","article-title":"Efficacy and safety of trimodulin (BT588) in subjects with severe community-acquired pneumonia (sCAP) (ESsCAPE) identifier: NCT05722938","year":"2023","journal-title":"ClinicalTrials.gov"},{"key":"B191","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3390\/biomedicines9070817","article-title":"The dual role of a polyvalent IgM\/IgA-enriched immunoglobulin preparation in activating and inhibiting the complement system","volume":"9","author":"Schmidt","year":"2021","journal-title":"Biomedicines."},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002372","article-title":"Pneumolysin induces platelet destruction, not platelet activation, which can be prevented by immunoglobulin preparations in vitro","volume":"4","author":"Jahn","year":"2020","journal-title":"Blood Adv"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1055\/a-1723-1880","article-title":"Polyvalent immunoglobulin preparations inhibit pneumolysin-induced platelet destruction","volume":"122","author":"Wiebe","year":"2021","journal-title":"Thromb Haemost."},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1177\/1753425919853333","article-title":"The novel polyclonal ab preparation trimodulin attenuates ex vivo endotoxin-induced immune reactions in early hyperinflammation","volume":"25","author":"Duerr","year":"2019","journal-title":"Innate Immun"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01043","article-title":"Plasma-derived polyreactive secretory-like IgA and IgM opsonizing salmonella enterica typhimurium reduces invasion and gut tissue inflammation through agglutination","volume":"8","author":"Bioley","year":"2017","journal-title":"Front Immunol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01213-16","article-title":"Improved protection in a rabbit model of community-associated methicillin-resistant staphylococcus aureus necrotizing pneumonia upon neutralization of leukocidins in addition to alpha-hemolysin","volume":"60","author":"Diep","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1038\/s41385-019-0167-z","article-title":"Topical application of human-derived ig isotypes for the control of acute respiratory infection evaluated in a human CD89-expressing mouse model","volume":"12","author":"Koernig","year":"2019","journal-title":"Mucosal Immunol"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03673-2","article-title":"Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants","volume":"595","author":"Ku","year":"2021","journal-title":"Nature."},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00290-15","article-title":"Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies","volume":"59","author":"Leyva-Grado","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.05.017","article-title":"EMAPII monoclonal antibody ameliorates influenza a virus-induced lung injury","volume":"26","author":"Lu","year":"2018","journal-title":"Mol Ther"},{"key":"B201","doi-asserted-by":"publisher","first-page":"100218","DOI":"10.1016\/j.xcrm.2021.100218","article-title":"Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters","volume":"2","author":"Piepenbrink","year":"2021","journal-title":"Cell Rep Med"},{"key":"B202","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12931-019-1057-3","article-title":"Topical application of nebulized human IgG, IgA and IgAM in the lungs of rats and non-human primates","volume":"20","author":"Vonarburg","year":"2019","journal-title":"Respir Res"},{"key":"B203","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/21645515.2019.1664243","article-title":"An intranasally administered monoclonal antibody cocktail abrogates ricin toxin-induced pulmonary tissue damage and inflammation","volume":"16","author":"Rong","year":"2020","journal-title":"Hum Vaccines Immunother."},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00128","article-title":"Inhibition of TNF receptor p55 by a domain antibody attenuates the initial phase of acid-induced lung injury in mice","volume":"8","author":"Wilson","year":"2017","journal-title":"Front Immunol"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-021-11488-4","article-title":"Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections","volume":"105","author":"Parray","year":"2021","journal-title":"Appl Microbiol Biotechnol"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2020.06.029","article-title":"Correlation and clinical relevance of animal models for inhaled pharmaceuticals and biopharmaceuticals","volume":"167","author":"S\u00e9cher","year":"2020","journal-title":"Adv Drug Delivery Rev"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.05.003","article-title":"Therapeutic antibodies: A new era in the treatment of respiratory diseases","volume":"189","author":"S\u00e9cher","year":"2018","journal-title":"Pharmacol Ther"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0136","article-title":"Add-on or alone? inhaled nebulized immunoglobulin reduces upper airway infections: 24 months of real-life experience","volume":"12","author":"Brodszki","year":"2020","journal-title":"Immunotherapy."},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199404000-00018","article-title":"Clinical experience with aerolized immunoglobulin treatment of respiratory syncytial virus infection in infants","volume":"13","author":"Rimensberger","year":"1994","journal-title":"Pedriatic Infect Dis J"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1080\/02786829308959603","article-title":"Lower respiratory tract structure of laboratory animals and humans: Dosimetry implications","volume":"18","author":"Miller","year":"1993","journal-title":"Aerosol Sci Technol"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2014.10.003","article-title":"Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system","volume":"196","author":"Guilleminault","year":"2014","journal-title":"J Controlled Release."},{"key":"B212","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3390\/pharmaceutics14030671","article-title":"Aggregates associated with instability of antibodies during aerosolization induce adverse immunological effects","volume":"14","author":"S\u00e9cher","year":"2022","journal-title":"Pharmaceutics."},{"key":"B213","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.3390\/pharmaceutics12111025","article-title":"Pulmonary delivery of biological drugs","volume":"12","author":"Liang","year":"2020","journal-title":"Pharmaceutics."},{"key":"B214","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cocis.2017.08.001","article-title":"PEGylation, an approach for improving the pulmonary delivery of biopharmaceuticals","volume":"31","author":"Guichard","year":"2017","journal-title":"Curr Opin Colloid Interface Sci"},{"key":"B215","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jconrel.2014.05.021","article-title":"PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract","volume":"187","author":"Koussoroplis","year":"2014","journal-title":"J Controlled Release."},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.05.015","article-title":"Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines","volume":"11","author":"Guo","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"B217","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12951-022-01307-x","article-title":"A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases","volume":"20","author":"He","year":"2022","journal-title":"J Nanobiotechnology."},{"key":"B218","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s43556-020-00014-z","article-title":"Developing inhaled protein therapeutics for lung diseases","volume":"1","author":"Matthews","year":"2020","journal-title":"Mol Biomed"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003189","article-title":"A novel human IgA monoclonal antibody protects against tuberculosis","volume":"186","author":"Balu","year":"2011","journal-title":"J Immunol"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/174.2.256","article-title":"Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection","volume":"174","author":"Weltzin","year":"1996","journal-title":"J Infect Dis"},{"key":"B221","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1183\/23120541.LSC-2022.73","article-title":"Human plasma-derived IgG protects against respiratory pathogens in an epithelial air-liquid interface model","volume-title":"Airway pharmacology and treatment. ERJ Open Research","author":"Graeter","year":"2022"},{"key":"B222","article-title":"Study to assess CSL787 in non-cystic fibrosis bronchiectasis (NCFB) Identifier: NCT04643587","year":"2020","journal-title":"ClinicalTrials.gov [Internet]"},{"key":"B223","article-title":"Engineering secretory IgA against infectious diseases","volume-title":"Immunosuppression and immunomodulation","author":"Falci Finardi","year":"2022"},{"key":"B224","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-76912-3_14","article-title":"Immunoglobulin a glycosylation and its role in disease","volume-title":"Editor Antibody glycosylation [Internet]","author":"Hansen","year":"2021"},{"key":"B225","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3390\/pathogens10060751","article-title":"Is SARS-CoV-2 neutralized more effectively by IgM and IgA than IgG having the same fab region","volume":"10","author":"Pisil","year":"2021","journal-title":"Pathogens"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2107148118","article-title":"Increased in vitro neutralizing activity of SARS-CoV-2 IgA1 dimers compared to monomers and IgG","volume":"118","author":"Sun","year":"2021","journal-title":"Proc Natl Acad Sci"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2022.2031483","article-title":"Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming","volume":"14","author":"Zhang","year":"2022","journal-title":"mAbs"},{"key":"B228","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1038\/s41467-020-18058-8","article-title":"A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction","volume":"11","author":"Ejemel","year":"2020","journal-title":"Nat Commun"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-1053315\/v1","article-title":"Recombinant neutralizing secretory IgA antibodies for preventing mucosal carriage and transmission of SARS-CoV-2","author":"G\u00f6ritzer","year":"2021","journal-title":"[Preprint] (Version 1)"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvab075","article-title":"Alternative strategies in cardiac preclinical research and new clinical trial formats","volume":"118","author":"Kreutzer","year":"2022","journal-title":"Cardiovasc Res"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.00549","article-title":"In vitro alternatives to acute inhalation toxicity studies in animal models\u2013a perspective","volume":"8","author":"Movia","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"key":"B232","doi-asserted-by":"publisher","first-page":"108516","DOI":"10.1016\/j.intimp.2021.108516","article-title":"Neutrophil extracellular traps (NETs) and covid-19: A new frontiers for therapeutic modality","volume":"104","author":"Al-Kuraishy","year":"2022","journal-title":"Int Immunopharmacol."},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.03.062","article-title":"CD89 is a potent innate receptor for bacteria and mediates host protection from sepsis","volume":"27","author":"de Tymowski","year":"2019","journal-title":"Cell Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1127339\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T01:57:47Z","timestamp":1679882267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1127339\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":233,"alternative-id":["10.3389\/fimmu.2023.1127339"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1127339","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]},"article-number":"1127339"}}